Management consensus guidance for the use of rivaroxaban - an oral, direct factor Xa inhibitor

摘要: A number of novel oral anticoagulants that directly target factor Xa or thrombin have been developed in recent years. Rivaroxaban and apixaban (direct inhibitors) dabigatran etexilate (a direct inhibitor) shown considerable promise large-scale, randomised clinical studies for the management thromboembolic disorders, approved use specific indications. is licensed prevention venous thromboembolism patients undergoing elective hip knee replacement surgery, treatment deep-vein thrombosis recurrent thromboembolism, stroke with non-valvular atrial fibrillation. Based on trial data rivaroxaban, feedback its practice authors’ experience practical guidance rivaroxaban special patient populations situations provided. Although most recommendations are line European summary product characteristics indications, additional and, several areas, different given based review literature experience.